by Chris Lee | Apr 3, 2016 | Options
My Thought Process Nearing the end of March, one of my top stock holdings, Keryx Biopharmaceuticals (NASDAQ: KERX) announced that they had a positive result from their phase 3 study of ferric citrate for the treatment of iron deficiency anemia in adults with... by Chris Lee | Dec 6, 2015 | Options
Today i sold January 2016 Put option for Keryx Bio-pharmaceuticals Current Implied Volatility= 98% Margin of safety for stock to fall before being exercised= 30% Strike price=4 USD Premium per contract= 13 USD Commission= 1.4 USD Return in 44 days time=...